An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation

NCT06466486
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Recruitment status
Terminated
clinicaltrials.gov
Participants
310
clinicaltrials.gov
Lead sponsor
Ferring Pharmaceuticals
clinicaltrials.gov
Start date
2024-06-14
clinicaltrials.gov
Number of sites
15
clinicaltrials.gov

Summary
This is a phase 1b clinical trial with Choriogonadotropin beta (FE999302) and Follitropin delta (Rekovelle). The trial is multicentre, randomized, partially double-blind, placebo-controlled, parallel-group investigating the effect of FE999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin. The primary endpoint is the number of good-quality blastocysts on day 5 after oocyte retrieval. Secondary endpoints are number of follicles by size category and serum concentration of different hormones on stimulation day 6 and end-of stimulation, the number of stimulation days and oocytes retrieved, the number of metaphase II oocytes and fertilised oocytes, number of blastocysts on day 5, number of cryopreserved blastocysts, endometrial thickness at eos, positive bhcg rate, clinical pregnancy, vital pregnancy and ongoing pregnancy.
clinicaltrials.gov
Acronym
Celestial-1
clinicaltrials.gov
Short title
An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation
clinicaltrials.gov
Official title
A Randomised, Partially Double-blind, Placebo-controlled, Parallel-group Exploratory Trial to Investigate the Effect of FE999302 in Women Undergoing Controlled Ovarian Stimulation With a Fixed Dose of Follitropin Delta in a Gonadotropin-releasing Hormone Antagonist Protocol
clinicaltrials.gov

Control arm
Placebo
clinicaltrials.gov
Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Terminated
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov
Reason stopped
This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.
clinicaltrials.gov

Completion date
2025-12-03
clinicaltrials.gov
First posted
2024-06-20
clinicaltrials.gov
Registry last updated
2026-03-30
clinicaltrials.gov
Primary completion date
2025-12-03
clinicaltrials.gov
Start date
2024-06-14
clinicaltrials.gov

Actual participants
310
clinicaltrials.gov
Participants
310
clinicaltrials.gov
Participant count basis
Actual
clinicaltrials.gov
Protocol amendments
5
clinicaltrials.gov
Number of sites
15
clinicaltrials.gov

Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Ferring Pharmaceuticals
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT06466486
clinicaltrials.gov
ClinicalTrials.gov ID
NCT06466486
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Randomised
Model
Parallel groups
Purpose
Treatment
Masking
Single masking
Masked roles
Outcome assessors
Sources for study design
clinicaltrials.gov

  1. Number of good-quality blastocysts

    Timeframe: Day 5 after oocyte retrieval.

    The number of good-quality blastocysts

  1. Number and size of follicles

    Timeframe: On stimulation day 6 and up to 20 days

    Number of follicles by size category

  2. Serum hormone concentrations

    Timeframe: On stimulation day 6, and up to 20 days

    Serum hormone concentrations of progesterone, 17-OH-progesterone, androstenedione, testosterone, estradiol, inhibin B, and luteinising hormone (LH) on stimulation day 6 and at end of stimulation.

  3. Serum hormone concentrations

    Timeframe: Up to 22 days

    Serum hormone concentrations of progesterone, 17-OH-progesterone, androstenedione, testosterone, and estradiol at oocyte retrieval

  4. Number of Stimulation days

    Timeframe: Up to 20 days

    Number of stimulation days

  5. Number of oocytes

    Timeframe: Up to 22 days

    Number of oocytes retrieved

  6. Number of metaphase II oocytes

    Timeframe: Up to 22 days

    Number of metaphase II (MII) oocytes

  7. Number of fertilised oocytes

    Timeframe: Up to 22 days

    Number of fertilised (2 pronuclei \[2PN\]) oocytes

  8. Number of blastocysts

    Timeframe: Up to 27 days

    Number of blastocysts

  9. Number of cryopreserved blastocysts

    Timeframe: Up to 28 days

    Number of cryopreserved blastocysts

  10. Endometrial thickness

    Timeframe: Up to 20 days, and up to 27 days

    Endometrial thickness

  11. Positive βhCG

    Timeframe: 13 to 15 days after fresh transfer

    Positive βhCG (positive serum βhCG test )

  12. Clinical pregnancy

    Timeframe: 5-6 weeks after fresh transfer

    Clinical pregnancy (at least one gestational sac)

  13. Vital pregnancy

    Timeframe: 5-6 weeks after fresh transfer

    Vital pregnancy (at least one intrauterine gestational sac with fetal heart beat)

  14. Ongoing pregnancy

    Timeframe: 10-11 weeks after fresh transfer

    Ongoing pregnancy (at least one intrauterine viable fetus)

Sources for outcomes
clinicaltrials.gov

Sex
Female
Age groups
Adults
Minimum age
18 Years
Maximum age
40 Years
Healthy volunteers
Yes

  1. Subject informed consent form signed before any trial-related activities.
  2. In good physical and mental health as judged by the investigator.
  3. Serum anti-Müllerian hormone (AMH) levels of 15.0-35.0 pmol/L at screening (measured at central laboratory).
  4. Pre-menopausal women between the ages of 18 and 40 years. The subjects must be at least 18 years (including the 18th birthday) and no more than 40 years (up to the day before the 41st birthday) when they sign the informed consent(s).
  5. Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II or with partners diagnosed with male factor infertility, eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor.
  6. Infertility for at least 1 year before screening for subjects <35 years or for at least 6 months for subjects ≥35 years (not applicable in case of tubal or severe male factor infertility).
  7. No more than two controlled ovarian stimulation cycles initiated, regardless of outcome (taking exclusion criteria 2 and 3 into account) and the subject must be suitable for treatment with 10 or 15 µg/day follitropin delta (corresponding to 150 or 225 IU).
  8. Regular menstrual cycles of 24-35 days (both inclusive), presumed to be ovulatory.
  9. Early follicular phase (cycle day 2-5) serum levels of follicle-stimulating hormone (FSH) between 1 and 15 IU/L (measured at central laboratory).
  10. Body mass index (BMI) between 18.0 and 30.0 kg/m2 (both inclusive) at screening.

  1. Known polycystic ovary syndrome (PCOS) or known endometriosis stage III-IV (American Society for Reproductive Medicine, 2012).
  2. Poor response in a previous controlled ovarian stimulation cycle using a gonadotropin starting dose of 150 IU/day or higher. Poor response is defined as <4 oocytes retrieved, or cycle cancellation before oocyte retrieval due to inadequate follicular development.
  3. Excessive ovarian response in a previous controlled ovarian stimulation cycle for IVF/ICSI using a daily FSH/ human menopausal gonadotropin (hMG) dose of ≤225 IU, defined as ≥25 oocytes retrieved or cycle cancellation before oocyte retrieval due to excessive ovarian response, including risk of ovarian hyperstimulation syndrome (OHSS).
  4. One or more follicles ≥10 mm (including cysts) observed on the transvaginal ultrasound before randomisation on stimulation day 1 (puncture of cysts is allowed before randomisation).
  5. Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy [excluding ectopic pregnancy] and before week 24 of pregnancy).
  6. Any known clinically significant systemic disease (e.g. insulin-dependent diabetes).
  7. Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver, or kidney) with the exception of controlled thyroid function disease.
  8. Known tumours of the ovary, breast, uterus, adrenal gland, pituitary, or hypothalamus which would contraindicate the use of gonadotropins.
  9. Any abnormal finding of clinical chemistry and haematology at screening or vital signs at randomisation, which is judged clinically relevant by the investigator and/or requires intervention.
  10. Currently breast-feeding.
  11. Undiagnosed vaginal bleeding.
  12. Findings at the gynaecological examination at screening which preclude gonadotropin stimulation or are associated with a reduced chance of pregnancy, e.g. congenital uterine abnormalities or retained intrauterine device.
  13. Pregnancy (negative urinary pregnancy tests must be documented at screening and before randomisation) or contraindication to pregnancy.
  14. Use of fertility modifiers during the last menstrual cycle before start of stimulation in the trial, including dehydroepiandrosterone (DHEA) and metformin or cycle programming with oral contraceptives, progestogen, or estrogen preparations
Sources for eligibility
clinicaltrials.gov

  • Ferring Investigational SiteBrussels, Belgium
  • Ferring Investigational SiteEdegem, Belgium
  • Ferring Investigational SitePrague, Czechia
  • Ferring Investigational SitePrague, Czechia
  • Ferring Investigational SitePrague, Czechia
  • Ferring Investigational SiteHvidovre, Denmark
  • Ferring Investigational SiteCopenhagen, Denmark
  • Ferring Investigational SiteTrondheim, Norway
  • Ferring Investigational SiteBergen, Norway
  • Ferring Investigational SitePorsgrunn, Norway
  • Ferring Investigational SiteMadrid, Spain
  • Ferring Investigational SiteBarcelona, Spain
  • Ferring Investigational SiteMadrid, Spain
  • Ferring Investigational SiteSeville, Spain
  • Ferring Investigational SiteValencia, Spain
Sources for sites
clinicaltrials.gov

  • 2023
  • 2023-507630-25-00
Sources for references
clinicaltrials.gov

Related records

Drugs (1)

Lead sponsors (1)

Targets (1)